Patients Stopping Anti-Obesity Medications Gain Back Weight at a Quadrupled Rate Than Dieters

New research indicates that patients who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who stop traditional diet and exercise regimens.

Research printed in a leading medical journal shows that while overweight individuals can lose a large proportion of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month after stopping.

"Individuals buying such medications should be aware of the danger of fast weight regain when the treatment concludes," cautioned researcher Dr. Susan Jebb.

That rate of recovery implies a return to starting weight in about 18 months.

Analyzing Approaches

The research, which looked at 37 of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with other pills.

Scientists point out that individuals who shed pounds through diet and exercise generally see a less rapid creep back—around 100 grams monthly—post-intervention.

Explaining the Rapid Regain

Experts suggest the mode of action of the jabs explains the accelerated regain.

GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.

"Long-term administration of the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating far more likely."

A Chronic Issue?

The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.

A number of clinicians say that, due to the high risk of relapse, the treatment is often long-term.

This view is echoed by drug manufacturers, who note that the findings "highlight the persistent nature of obesity," akin to managing diseases like high blood pressure.

User Experiences

Individuals who have stopped the medication explain a intense return of hunger.

"It was like a trigger activating and you become ravenous," said a patient.

This challenge is compounded if individuals have not developed lasting lifestyle or habit changes during treatment.

Growing Adoption

Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the past year, with demand being substantial.

• Adoption is more common among women compared to men.
• The 40s and 50s demographic shows the highest usage rates.
• A large proportion access the medications through private healthcare rather than public health services.

Finally, researchers stress that while the jabs are powerful tools for shedding pounds, they are not a standalone cure and maintained weight loss relies on integrated lifestyle changes.